Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, United States.
Front Endocrinol (Lausanne). 2022 Nov 25;13:1037211. doi: 10.3389/fendo.2022.1037211. eCollection 2022.
We performed a matched cohort study among individuals with and without nonalcoholic fatty liver disease (NAFLD) to determine: 1) the incidence of cancers (extrahepatic and liver) and their spectrum and 2) if NAFLD increases the risk of extrahepatic cancers.
The NAFLD and non-NAFLD (control) cohorts were identified from electronic medical records International Classification of Diseases (ICD) codes from a single center and followed from 2010 to 2019. Cohorts were matched 1:2 for age, sex, race, body mass index (BMI), and type 2 diabetes.
A total of 1,412 subjects were included in the analyses. There were 477 individuals with NAFLD and 935 controls (median age, 52 years; women, 54%; white vs. black: 59% vs. 38%; median BMI, 30.4 kg/m; type 2 diabetes, 34%). The cancer incidence (per 100,000 person-years) was 535 vs. 1,513 (NAFLD vs. control). Liver cancer incidence (per 100,000 person-years) was 89 in the NAFLD group vs. 0 in the control group, whereas the incidence of malignancy was higher across other types of cancer in the control group vs. in the NAFLD group.
The overall extrahepatic cancer risk in NAFLD is not increased above and beyond the risk from background risk factors such as age, race, sex, BMI, and type 2 diabetes.
我们对患有非酒精性脂肪性肝病(NAFLD)和不患有非酒精性脂肪性肝病(对照组)的个体进行了匹配队列研究,以确定:1)癌症(肝外和肝内)的发病率及其谱;2)NAFLD 是否增加肝外癌症的风险。
从一个中心的电子病历和国际疾病分类(ICD)代码中确定了 NAFLD 和非-NAFLD(对照组)队列,并从 2010 年到 2019 年进行随访。队列按年龄、性别、种族、体重指数(BMI)和 2 型糖尿病进行 1:2 匹配。
共纳入 1412 名受试者进行分析。NAFLD 组 477 人,对照组 935 人(中位年龄 52 岁;女性 54%;白种人 vs. 黑人:59% vs. 38%;中位 BMI 30.4kg/m;2 型糖尿病 34%)。癌症发病率(每 100,000 人年)为 535 比 1,513(NAFLD 比对照组)。NAFLD 组肝癌发病率(每 100,000 人年)为 89,对照组为 0,而对照组其他类型癌症的恶性肿瘤发病率高于 NAFLD 组。
NAFLD 患者的总体肝外癌症风险并未超过年龄、种族、性别、BMI 和 2 型糖尿病等背景风险因素所带来的风险。